Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01489891
Other study ID # 2011-005704-15
Secondary ID ATF-EGD001
Status Completed
Phase Phase 4
First received December 3, 2011
Last updated March 7, 2013
Start date December 2011
Est. completion date August 2012

Study information

Verified date March 2013
Source Hospital Universitario Infanta Cristina
Contact n/a
Is FDA regulated No
Health authority Spain: Agencia Española de Medicamentos y Productos SanitariosSpain: Comité Ético de Investigación Clínica
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the efficacy of application of the anaesthesia topical pharyngeal with lidocaine in esophagogastroduodenoscopy under propofol´s sedation, in therms of dosage and side effect´s reduction overall.


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date August 2012
Est. primary completion date July 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patient´s over 18 years old that received standard indication for sedated esophagogastroduodenoscopy (American Society of Gastrointestinal Endoscopy Guidelines) in our centre between the period of study.

Exclusion Criteria:

- Patients under 18 years old

- Unable to obtain inform´s consent

- Emergency endoscopy

- Pregnant women

- Encephalopathy

- Well known allergic reaction to propofol, amide-anaesthesics, soy or eggs

- Methaemoglobinemia induced factor risks

- No previous or unknown fasting

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Drug:
Lidocaine
Applying of 5 puff controlled released (50 mg) transoral spray of lidocaine (10 mg=1 puff).
Placebo
Applying of 5 puff controlled released (50 mg) transoral spray of placebo (excipients of trade mark of lidocaine ensuring the patient masking).

Locations

Country Name City State
Spain Hospital Universitario Infanta Cristina Parla Madrid

Sponsors (1)

Lead Sponsor Collaborator
Hospital Universitario Infanta Cristina

Country where clinical trial is conducted

Spain, 

References & Publications (7)

Amornyotin S, Srikureja W, Chalayonnavin W, Kongphlay S, Chatchawankitkul S. Topical viscous lidocaine solution versus lidocaine spray for pharyngeal anesthesia in unsedated esophagogastroduodenoscopy. Endoscopy. 2009 Jul;41(7):581-6. doi: 10.1055/s-0029- — View Citation

Dumonceau JM, Riphaus A, Aparicio JR, Beilenhoff U, Knape JT, Ortmann M, Paspatis G, Ponsioen CY, Racz I, Schreiber F, Vilmann P, Wehrmann T, Wientjes C, Walder B; NAAP Task Force Members. European Society of Gastrointestinal Endoscopy, European Society o — View Citation

Evans LT, Saberi S, Kim HM, Elta GH, Schoenfeld P. Pharyngeal anesthesia during sedated EGDs: is "the spray" beneficial? A meta-analysis and systematic review. Gastrointest Endosc. 2006 May;63(6):761-6. Review. — View Citation

Jiménez-Puente G, Hidalgo-Isla M. [Use of topical pharyngeal anaesthesia in esophagogastroduodenoscopy in unsedated patients]. Enferm Clin. 2011 Jan-Feb;21(1):30-4. doi: 10.1016/j.enfcli.2010.07.008. Epub 2011 Feb 18. Spanish. — View Citation

Lachter J, Jacobs R, Lavy A, Weisler A, Suissa A, Enat R, Eidelman S. Topical pharyngeal anesthesia for easing endoscopy: a double-blind, randomized, placebo-controlled study. Gastrointest Endosc. 1990 Jan-Feb;36(1):19-21. — View Citation

Mulcahy HE, Greaves RR, Ballinger A, Patchett SE, Riches A, Fairclough PD, Farthing MJ. A double-blind randomized trial of low-dose versus high-dose topical anaesthesia in unsedated upper gastrointestinal endoscopy. Aliment Pharmacol Ther. 1996 Dec;10(6): — View Citation

Ristikankare M, Hartikainen J, Heikkinen M, Julkunen R. Is routine sedation or topical pharyngeal anesthesia beneficial during upper endoscopy? Gastrointest Endosc. 2004 Nov;60(5):686-94. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of Administration of Propofol 1% Required to Obtain Uniform Sedation During Endoscopy The propofol will be administered by an expert anaesthetist in repeated bolus (10-20 mg each 30-60 seconds) after an initial induction dosage (0.5-0.6 mg/kg ASA (American Society of Anaesthesiologists) I-II or 0.25-0.35 mg/kg ASA III-IV) to obtain an uniform level of sedation (OAAS 3 and bispectral index (BIS) 70-80) and adequate perceived patient tolerance (no gag-reflex, cough, sudden movements). 8 months No
Secondary Percentage of Participants With Adverse Events in Both Groups Hypoxemia (SatO2<90% or >4% if the baseline was under 93%), bradycardia (<60 bpm or >10% from baseline), hypotension (systolic blood pressure under 90 mmHg and/or diastolic 60 mmHg), anaphylactic reaction, aspiration o methaemoglobinemia. Participants will be followed for the duration of hospital stay, an expected average of 2 hours postprocedure Yes
Secondary Likert Four Elements Scale to Evaluate the Satisfaction of Endoscopist Define as easiness to reach the expected objectives for endoscopy without patient interference: very satisfied, satisfied, neutral, unsatisfied. 8 months No
Secondary Likert Four Elements Scale to Evaluate the Satisfaction of Anaesthetist Define as easiness to reach and maintain the level of sedation and patient comfort during endoscopy: very satisfied, satisfied, neutral, unsatisfied. 8 months No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02264249 - Residual Gastric Volume in Same Day Versus Split Dose and Evening Before Bowel Preparation N/A
Terminated NCT04168294 - The Influence of Sedation for Endoscopy on Cognitive Function
Enrolling by invitation NCT04725695 - Preoperative Viscous Lidocaine for Upper Gastrointestinal Endoscopy Phase 4
Completed NCT03883035 - Quality Control of Esophagogastroduodenoscopy Using Real-time EGD Auxiliary System N/A
Recruiting NCT05407870 - Efficacy and Safety of Etomidate Sedation in Gastric Endoscopic Submucosal Dissection N/A
Completed NCT01547520 - Meperidine as the Single Sedative Agent During Esophagogastroduodenoscopy N/A
Completed NCT05504434 - Performance of a Single-use Gastroscope (aScope Gastro) for Esophagogastroduodenoscopy N/A
Completed NCT02215291 - NvisionVLE™ Registry System Registry
Completed NCT04720924 - AQCS for Detection of Early Cancer and Precancerous Lesions on Upper Gastrointestinal Tract N/A
Recruiting NCT03070379 - Topical Pharyngeal Anesthesia in Sedated Esophagogastroduodenoscopy N/A
Completed NCT04247399 - Simulation-assisted Teaching in Learning Gastroscopy N/A